DocWire News Editors

DocwireNews

The U.S. Food and Drug Administration (FDA) currently has about 200 pending orphan drug designation requests, according to experts at a session on the orphan drugs in the development pipeline and strategies for managing these expensive therapies.Last year, the FDA released a &ldquo;90 in 90 Plan,&rdquo; which states that in 90 days the FDA will complete reviews of all orphan drug designation requests that are older than 120 days. After 90 days, 100% of all new requests will receive a response by the agency within 90 days of receipt.Furthermore, in December 2017 the FDA issued draft guidance that it will no longer grant orphan drug designations to pediatric subpopulations unless the disease constitutes a valid orphan subset and the sponsor can adequately demonstrate that the disease in the pediatric population is different from that of adults, as well as meeting all other criteria for this designation.During a presentation at AMCP Annual Meeting 2018,&nbsp;Christine Bui, PharmD, BCPS,&nbsp;a drug information pharmacist, and&nbsp;Stephen Jung, PharmD, BCPS,&nbsp;a manager of drug information, both of MedImpact Healthcare Systems, Inc., highlighted drugs in development for key rare disease areas and current management strategies.Disease states in which products are under development include:<ul>
<li>Spinal Muscular Atrophy (SMA), a rare, autosomal recessive neuromuscular disorder characterized by degeneration of motor neurons of the spinal cord, resulting in severe and progressive atrophy of skeletal muscles and generalized weakness. In 2016, nusinersen was approved for SMA in adults in children. The phase III SMA pipeline includes AVXS-101 and RG7916.</li>
<li>Ceroid Lipofuscinosis Type 2 (CLT2), an autosomal recessive, neurodegenerative lysosomal storage disorder caused by deficiency of tripeptidyl peptidase 1 enzyme. In 2017, cerliponase alfa was approved to slow the loss of ambulation in symptomatic pediatric patients with late infantile CLN2. The phase I/II CLN2 pipeline includes AAVrh10, which is a gene therapy.</li>
<li>Amyotrophic Lateral Sclerosis (ALS), a rapidly progressing neurodegenerative disorder characterized by motor neuron degeneration in the spinal cord, brainstem, and motor cortex. In 2017, edaravone was approved for ALS. The phase III ALS pipeline includes masitinib and NurOwn, which is a stem cell therapy.</li>
</ul>Payer sensitivity of these agents continues to rise, as annual costs range in the hundreds of thousands per patient and few&mdash;if any&mdash;have alternative agents available for the rare disease. As a result, payers have changed the benefit design to manage utilization and spend, which includes formulary restrictions and specialty tier, shifting from copayments to coinsurance, and using prior authorization.An analysis of reimbursement data found that orphan drugs have more coverage restrictions than non-orphan drugs, with prior authorizations used most widely. Prior authorization criteria for these agents include documentation of clinical diagnosis, appropriate patient age, prescriber specialty, baseline data (including genetic screening and laboratory values), renewal criteria (including documentation of response), and quantity limit.Presentation S4: The Rise of Orphan Drugs: The Increasingly Common Challenge of Managing Rare Diseases. AMCP Annual Meeting 2018.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Orphan Drug Outlook and the Management of These Agents

AMCP 2018

The U.S. Food and Drug Administration (FDA) currently has about 200 pending orphan drug designation requests, according to experts at a session on the orphan drugs in the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe